(NASDAQ: ATHA) Athira Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.71%.
Athira Pharma's earnings in 2025 is -$79,746,000.On average, 1 Wall Street analyst forecast ATHA's earnings for 2025 to be -$29,672,258, with the lowest ATHA earnings forecast at -$29,672,258, and the highest ATHA earnings forecast at -$29,672,258.
In 2027, ATHA is forecast to generate -$8,198,913 in earnings, with the lowest earnings forecast at -$8,198,913 and the highest earnings forecast at -$8,198,913.